Several years after its launching to the market, the medicine shows high effectiveness because of its cicatrizant properties in stubborn ulcers, Dr. Manuel Raices, a specialist of the Center of Genetic Engineering and Biotechnology, said in a press conference.
He said a clinical trial phase III with the product started yesterday in China in order to start the registration, introduction and extension of this new therapy in that country.
Another clinical trial phase III will start in Europe early next year, covering 11 nations, 100 prestigious medical centers and more than 700 patients.
The treatment with Heberprot-P has meant a revolution in managing patients with diabetic foot ulcers leading irreversibly to amputation.
The mechanism of cicatrization fails and infections cannot be controlled in people with diabetes, noted Raices.
Heberprot-P was subject to a long process of research and trials to validate its effectiveness, and it is now available in 43 hospitals and 197 community-based polyclinics in Cuba.
He has also been licensed in the United States, the European Union, Australia, Japan, Hong Kong, South Korea, China, India, Russia, Singapore, Indonesia, South Africa, Mexico, Malaysia, Ukraine, Argentina and Cuba, and registered in other countries.
The expert revealed that nano research on the medicine is being carried out, looking for new, more effective, lower-cost generations of the product.
All these issues are expected to be discussed in the International Congress Heberprot-P 2012, to be held on Dec.12-14 at Havana Convention Center.